Abcam, ab137606, Anti-CES2 antibody

Size: 100µL
Rabbit Polyclonal EST2 antibody. Suitable for WB, ICC/IF, IHC-P and reacts with Human samples. Cited in 2 publications. Immunogen corresponding to Recombinant Fragment Protein within Human CES2 aa 50-500.
Key facts
Host species:Rabbit,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:ICC/IF, WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Recombinant Fragment Protein within Human CES2 aa 50-500. The exact immunogen used to generate this antibody is proprietary information.O00748

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Immunogen, Storage buffer-pH: 7Preservative: 0.01% Thimerosal (merthiolate)Constituents: 10% Glycerol (glycerin, glycerine), 1.21% Tris, 0.75% Glycine, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Carboxylesterase 2 (CES2) also known as intestinal carboxylesterase is an enzyme with a molecular mass of approximately 60 kDa. CES2 hydrolyzes esters and amides affecting metabolism of drugs and xenobiotics. It is found mainly in the liver and small intestine with lesser expression in the colon kidney and brain. This distribution enables CES2 to play a role in both intestinal and systemic drug metabolism.
Biological function summary
CES2 acts in the hydrolysis process converting prodrugs into active compounds. It functions independently and is not typically part of a larger complex. This enzyme demonstrates broad substrate specificity impacting the metabolic activation of several therapeutic agents. Its activity affects the bioavailability and activation of medicines such as irinotecan and capecitabine which are used in cancer treatments.
Pathways
CES2 takes part in the drug metabolism pathway involving cytochrome P450 enzymes. It interacts with CYP3A4 one of the key enzymes in this system and facilitates the conversion of chemical compounds into pharmacologically active or inactive metabolites. CES2 also participates in lipid metabolism affecting the ester and triglyceride hydrolysis alongside lipases and other related enzymes.
CES2 has implications in colorectal cancer and liver disease conditions where altered drug metabolism influences disease progression and treatment efficacy. It shows associations with irinotecan activation a drug used for treating colorectal cancer and links with UDP-glucuronosyltransferases (UGTs) that also engage in drug metabolism. Understanding CES2's function aids in predicting patient responses to drug therapies and refining treatment strategies for these conditions.